SAS Output

13-JUL-2020 6:10

LEUK ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1318-ALL, Age 65+, Ph±, Blinatumomab 1 Y 1 Induction: Ph- 58 31 0 0 0 0 0 06/30/2015 118 45
        2 Induction: Ph+/Ph-like   24 8 4 1 0 0      
            55 8 4 1 0 0      
 
    2 Y 3 Post-remission: Ph- 58 20 0 0 0 0 0 06/30/2015    
        4 Post-remission: Ph+/Ph-like   18 6 5 3 0 0      
            38 6 5 3 0 0      
 
    3 Y 5 Maintenance: Ph- 58 14 0 0 0 0 0 06/30/2015    
        6 Maintenance: Ph+/Ph-like   13 3 3 3 1 1      
            27 3 3 3 1 1      
 
  S1612-AML/MDS, Age 60+, Aza/Novel Therapeutics 1 T 0 FLT3 Testing 1670 113 0 0 0 0 0 02/02/2018 204 83
            113 0 0 0 0 0      
 
    2 T 1 Azacitidine 1670 26 0 0 0 0 0 02/02/2018    
        2 Azacitidine + Nivolumab   26 0 0 0 0 0      
        3 Azacitidine + Midostaurin   26 0 0 0 0 0      
            78 0 0 0 0 0      
 
  S1712-CML, Chronic Phase, TKI +/- Ruxolitinib 1 Y 1 Single Agent TKI 84 15 11 5 0 0 0 10/24/2018 183 68
        2 TKI + Ruxolitinib   15 12 7 3 1 1      
            30 23 12 3 1 1      
 
Yes A041701-AML, Age 60+, Conv Chemo +/- Uproleselan 0 E Total Registrations   22 17 10 2 2 1 06/10/2019 140 58
            22 17 10 2 2 1      
 
    1 E Total Registrations   13 11 7 1 1 0 06/10/2019    
            13 11 7 1 1 0      
 
  A041702-CLL, Stg I-IV, IO with IM versus IVO 0 E Total Registrations   31 23 8 4 3 1 03/04/2019 284 120
            31 23 8 4 3 1      
 
    1 E Total Registrations   26 21 6 2 2 0 03/04/2019    
            26 21 6 2 2 0      
 
    2 E Total Registrations   2 2 2 2 0 0 03/04/2019    
            2 2 2 2 0 0      
 
  EA9161-CLL, untreated, IOV vs IO in younger pts 0 E Total Registrations   60 60 33 11 7 3 02/12/2019 278 124
            60 60 33 11 7 3      
 
    1 E Total Registrations   106 76 36 9 5 4 02/12/2019    
            106 76 36 9 5 4      
 
No A041501-B-Cell ALL, Frontline Tx +/- Intuzumab Ozo 0 E Total Registrations   27 20 14 5 1 0 11/09/2018 199 77
            27 20 14 5 1 0      
 
    1 E Total Registrations   22 18 12 6 1 0 11/09/2018    
            22 18 12 6 1 0      
 
    2 E Total Registrations   13 12 7 2 0 0 11/09/2018    
            13 12 7 2 0 0      
 
  EA9171-CML, Anti-PD-1 Pembrolizumab + TKIs 0 E Total Registrations   1 1 1 0 0 0 02/18/2020 1 2
            1 1 1 0 0 0      
 
    1 E Total Registrations   1 1 1 0 0 0 02/18/2020    
            1 1 1 0 0 0